Contineum Therapeutics
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical enterprise headquartered in San Diego, California. The company specializes in the discovery and development of novel small-molecule therapeutics targeting specialized biological pathways for the treatment of neuroscience, inflammation, and autoimmune conditions. Its proprietary research engine designs selective oral medications to address unmet medical needs. Principal revenue is currently earned through strategic pharmaceutical partnerships, research collaborations, and capital financing arrangements as its drug candidates advance through clinical development. Contineum Therapeutics Inc is publicly listed on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Contineum Therapeutics.
- Legal name
- Contineum Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Contineum Therapeutics
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.71 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)